68 research outputs found
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π»Π΅ΠΊΠ°ΡΡΡΠ² ΠΈ ΠΎΡΠΊΡΡΡΡΠΉ Π΄ΠΎΡΡΡΠΏ: ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ
The development of a new medicine is a process that requires enormous time and tremendous financing. It takes 10-15 years from the discovery of an active compound to the launch of its production and the start of drug marketing with the total costs of the project reaching 1.8 billion US dollars. These large time and financial costs stem from repeated testing and elimination of a large percentage of compounds over the course of screening at each stage of preclinical and clinical trials. Many investors have lost interest in financing new drug discovery projects (or pharmaceutical start-up companies) due to the high risk and extensive time required to produce a return on investments. Since all the research data are considered confidential by pharmaceutical companies and thus never shared with scientific community, different scientific groups waste significant resources repeating the same costly experiments in drug discovery. In this article, we discuss new approaches to drug discovery involving open access to the research data and alternative financing that could significantly streamline the search for new cures for human diseases.Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π½ΠΎΠ²ΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π° β ΠΏΡΠΎΡΠ΅ΡΡ, ΡΡΠ΅Π±ΡΡΡΠΈΠΉ ΠΊΠΎΠ»ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
Π·Π°ΡΡΠ°Ρ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΈ ΡΠΈΠ½Π°Π½ΡΠΎΠ²ΡΡ
ΡΡΠ΅Π΄ΡΡΠ². ΠΡ Π½Π°Ρ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΡΡ
Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Π΄ΠΎ Π²ΡΡ
ΠΎΠ΄Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π½Π° ΡΡΠ½ΠΎΠΊ ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΡ 10-15 Π»Π΅Ρ ΠΈ ΡΠ°ΡΡ
ΠΎΠ΄ΡΠ΅ΡΡΡ ΠΏΠΎΡΡΠ΄ΠΊΠ° 1.8 ΠΌΠΈΠ»Π»ΠΈΠ°ΡΠ΄Π° Π΄ΠΎΠ»Π»Π°ΡΠΎΠ². Π’Π°ΠΊΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΈ ΡΡΠΌΠΌΡ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Ρ Π±ΠΎΠ»ΡΡΠΈΠΌ ΠΏΡΠΎΡΠ΅Π½ΡΠΎΠΌ ΠΎΡΡΠ΅Π²Π° Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Π½Π° ΠΊΠ°ΠΆΠ΄ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΠΏΡΡΠ°Π½ΠΈΠΉ. ΠΠ½ΠΎΠ³ΠΈΠ΅ ΠΈΠ½Π²Π΅ΡΡΠΎΡΡ ΠΏΠΎΡΠ΅ΡΡΠ»ΠΈ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ ΠΊ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ°ΡΡΠ°ΠΏΠΎΠ² ΠΈ ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² ΠΏΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π½ΠΎΠ²ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈΠ·-Π·Π° Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠ³ΠΎ Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΡΠΈΠ±ΡΠ»ΠΈ ΠΎΡ ΠΈΠ½Π²Π΅ΡΡΠΈΡΠΈΠΉ. ΠΠΎΡΠΊΠΎΠ»ΡΠΊΡ Π²ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ°Ρ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΡΠΌ, ΡΡΠΈΡΠ°ΡΡΡΡ ΠΊΠΎΠ½ΡΠΈΠ΄Π΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΈ ΠΏΠΎΡΡΠΎΠΌΡ Π½Π΅Π΄ΠΎΡΡΡΠΏΠ½Ρ Π΄Π»Ρ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Π°, Π½Π°ΡΡΠ½ΡΠ΅ ΠΊΠΎΠ»Π»Π΅ΠΊΡΠΈΠ²Ρ ΡΡΠ°ΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅ΡΡΡΡΡ, ΠΏΠΎΠ²ΡΠΎΡΡΡ ΠΎΠ΄Π½ΠΈ ΠΈ ΡΠ΅ ΠΆΠ΅ Π΄ΠΎΡΠΎΠ³ΠΎΡΡΠΎΡΡΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΡ. Π ΡΡΠΎΠΌ ΠΎΠ±Π·ΠΎΡΠ΅ ΠΌΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΠΌ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠΈΠ½ΡΠΈΠΏΡ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠ°Π±ΠΎΡΡ ΠΏΠΎ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ Π½ΠΎΠ²ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ² β ΠΎΡΠΊΡΡΡΡΠΉ Π΄ΠΎΡΡΡΠΏ ΠΊ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΠΎΠ΅ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠΈΡ
ΠΏΡΠΈΠ½ΡΠΈΠΏΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠΏΡΠΎΡΡΠΈΡΡ ΠΈ ΡΠ΄Π΅ΡΠ΅Π²ΠΈΡΡ ΠΏΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π»ΡΠ΄Π΅ΠΉ
Novel Biodegradable Polymeric Microparticles Facilitate Scarless Wound Healing by Promoting Re-epithelialization and Inhibiting Fibrosis
Despite decades of research, the goal of achieving scarless wound healing remains elusive. One of the approaches, treatment with polymeric microcarriers, was shown to promote tissue regeneration in various in vitro models of wound healing. The in vivo effects of such an approach are attributed to transferred cells with polymeric microparticles functioning merely as inert scaffolds. We aimed to establish a bioactive biopolymer carrier that would promote would healing and inhibit scar formation in the murine model of deep skin wounds. Here we characterize two candidate types of microparticles based on fibroin/gelatin or spidroin and show that both types increase re-epithelialization rate and inhibit scar formation during skin wound healing. Interestingly, the effects of these microparticles on inflammatory gene expression and cytokine production by macrophages, fibroblasts, and keratinocytes are distinct. Both types of microparticles, as well as their soluble derivatives, fibroin and spidroin, significantly reduced the expression of profibrotic factors Fgf2 and Ctgf in mouse embryonic fibroblasts. However, only fibroin/gelatin microparticles induced transient inflammatory gene expression and cytokine production leading to an influx of inflammatory Ly6C+ myeloid cells to the injection site. The ability of microparticle carriers of equal proregenerative potential to induce inflammatory response may allow their subsequent adaptation to treatment of wounds with different bioburden and fibrotic content
Voltammetry and single-molecule in situ scanning tunneling microscopy of laccases and bilirubin oxidase in electrocatalytic dioxygen reduction on Au(111) single-crystal electrodes
ΠΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π° ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π±ΠΈΠΎΠ³Π΅Π½Π½ΡΡ ΠΊΠ²Π°Π½ΡΠΎΠ²ΡΡ ΡΠΎΡΠ΅ΠΊ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΡΡΠ»ΡΡΠΈΠ΄ΠΎΠ² ΡΠ΅ΡΠ΅Π±ΡΠ°, ΠΊΠ°Π΄ΠΌΠΈΡ ΠΈ ΡΠΈΠ½ΠΊΠ° Π΄Π»Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ Π±ΠΈΠΎΠ½Π°Π½ΠΎΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠ½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ²
The possibility of applying silver, cadmium and zinc sulfide nanoparticles (npAg2S, npCdS and npZnS) obtained using Shewanella oneidensis MR-1 and Bacillus subtilis 168 bacterial cultures for the creation of a new class of polymeric bionanocomposite materials was investigated. Biogenic nanoparticles obtained in aqueous solutions of the corresponding salts in the presence of various types of microorganisms are characterized by the presence of protein molecules on their surface. The molecules composition is determined by the bacterial culture. Proteins stabilize them and allow the nanoparticles to covalently join the active groups of polymeric carriers. Aminated chloromethylated polystyrene microspheres, as well as ion-exchange resins of various types, were used as polymeric matrices. Analysis of interaction with them can be used as a method for studying the properties of biogenic nanoparticles of metal sulfides for subsequent successful selection of a polymeric carrier. The immobilization of biogenic nanoparticles of metal sulfides onto the surface of aminated chloromethylated polystyrene microspheres was found to depend on the level of stability of aqueous nanoparticle suspensions and is determined by the negative charge of biogenic npAg2S, npCdS and npZnS, which suggests covalent binding and the electrostatic interaction of the components in the composition of the polymer bionanocomposite. A comparative analysis of the parameters of nanoparticles depending on the strain used in the biosynthesis was carried out. Analysis of the main physicochemical characteristics of npCdS and npZnS showed that the small size of nanoparticles (npCdS - 5 nm, npZnS - up to 2 nm) and the presence of luminescence peaks at wavelengths less than 400 nm classify them in the blue region of the fluorescence spectrum and identify them as quantum dots. Thus, the possibility of introducing fluorescent quantum dots of nanoparticles of metal sulfides of biogenic origin into various polymeric matrices has been demonstrated, which contributes to the expansion of the horizons for using a new class of nanoparticles to create polymeric bionanocomposites.ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΡΡΠ»ΡΡΠΈΠ΄Π° ΡΠ΅ΡΠ΅Π±ΡΠ°, ΠΊΠ°Π΄ΠΌΠΈΡ ΠΈ ΡΠΈΠ½ΠΊΠ° (npAg2S, npCdS ΠΈ npZnS), ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΊΡΠ»ΡΡΡΡ Shewanella oneidensis MR-1 ΠΈ Bacillus subtilis 168, Π΄Π»Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ
Π±ΠΈΠΎΠ½Π°Π½ΠΎΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ². ΠΠΈΠΎΠ³Π΅Π½Π½ΡΠ΅ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡΡ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π² Π²ΠΎΠ΄Π½ΡΡ
ΡΠ°ΡΡΠ²ΠΎΡΠ°Ρ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΡΠΎΠ»Π΅ΠΉ Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΈΠΏΠΎΠ² ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ², Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π½Π° ΠΈΡ
ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π±Π΅Π»ΠΊΠΎΠ²ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ», ΡΠΎΡΡΠ°Π² ΠΊΠΎΡΠΎΡΡΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΡΠ»ΡΡΡΡΠΎΠΉ. ΠΠ΅Π»ΠΊΠΈ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·ΠΈΡΡΡΡ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡΡ ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΈΠΌ ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΠΎ ΠΏΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½ΡΡΡΡΡ ΠΊ Π°ΠΊΡΠΈΠ²Π½ΡΠΌ Π³ΡΡΠΏΠΏΠ°ΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ
Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ
ΠΌΠ°ΡΡΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π°ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Ρ
Π»ΠΎΡΠΌ,Π΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½-Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΡΡΠΈΡΠΎΠ»ΡΠ½ΡΠ΅ ΠΌΠΈΠΊΡΠΎΡΡΠ΅ΡΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΠΎΠ½ΠΎΠΎΠ±ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠΌΠΎΠ»Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΈΠΏΠΎΠ². ΠΠ½Π°Π»ΠΈΠ· Π²Π·Π°ΠΈΠ»ΡΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Ρ Π½ΠΈΠΌΠΈ Π»ΡΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π»ΡΠ΅ΡΠΎΠ΄Π° ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² Π±ΠΈΠΎΠ³Π΅Π½Π½ΡΡ
Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΡΡΠ»ΡΡΠΈΠ΄ΠΎΠ² ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² Π΄Π»Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅Π³ΠΎ ΡΡΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ±ΠΎΡΠ° ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π½ΠΎΡΠΈΡΠ΅Π»Ρ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π±ΠΈΠΎΠ³Π΅Π½Π½ΡΡ
Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΡΡΠ»ΡΡΠΈΠ΄ΠΎΠ² ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² Π½Π° ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π°ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ
Π»ΠΎΡΠΌΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎΠ»ΠΈΡΡΠΈΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΠΈΠΊΡΠΎΡΡΠ΅Ρ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΡΠΎΠ²Π½Ρ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ Π²ΠΎΠ΄Π½ΡΡ
ΡΡΡΠΏΠ΅Π½Π·ΠΈΠΉ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌ Π·Π°ΡΡΠ΄ΠΎΠΌ Π±ΠΈΠΎΠ³Π΅Π½Π½ΡΡ
npAg2S, npCdS ΠΈ npZnS, ΡΡΠΎ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅Ρ ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΠ΅ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ ΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π±ΠΈΠΎΠ½Π°Π½ΠΎΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠ°. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠ°ΠΌΠΌΠ°, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΠΎΠ³ΠΎ Π² Π±ΠΈΠΎΡΠΈΠ½ΡΠ΅Π·Π΅. ΠΠ½Π°Π»ΠΈΠ· ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ npCdS ΠΈ npZnS ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π½Π΅Π±ΠΎΠ»ΡΡΠΈΠ΅ ΡΠ°Π·ΠΌΠ΅ΡΡ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ (npCdS - 5 Π½ΠΌ, npZnS - Π΄ΠΎ 2 Π½ΠΌ) ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ Π»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠ½ΡΡ
ΠΏΠΈΠΊΠΎΠ² Π½Π° Π΄Π»ΠΈΠ½Π°Ρ
Π²ΠΎΠ»Π½ ΠΌΠ΅Π½Π΅Π΅ 400 Π½ΠΌ, ΡΡΠΎ ΠΎΡΠ½ΠΎΡΠΈΡ ΠΈΡ
ΠΊ ΡΠΈΠ½Π΅ΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΡΠΏΠ΅ΠΊΡΡΠ° ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΊΠ»Π°ΡΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°ΡΡ ΠΈΡ
ΠΊΠ°ΠΊ ΠΊΠ²Π°Π½ΡΠΎΠ²ΡΠ΅ ΡΠΎΡΠΊΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±ΡΠ»Π° ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΡΡ
ΠΊΠ²Π°Π½ΡΠΎΠ²ΡΡ
ΡΠΎΡΠ΅ΠΊ Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ ΡΡΠ»ΡΡΠΈΠ΄ΠΎΠ² ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² Π±ΠΈΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΠ΅ ΠΌΠ°ΡΡΠΈΡΡ, ΡΡΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ Π³ΠΎΡΠΈΠ·ΠΎΠ½ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° Π½Π°Π½ΠΎΡΠ°ΡΡΠΈΡ Π΄Π»Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ
Π±ΠΈΠΎΠ½Π°Π½ΠΎΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΎΠ²
Amino acids and peptides. XLII. A synthesis of dethiooxytocin and other acyclic peptides related to oxytocin
- β¦